Summary
Eli Lilly's Q2 sales soared, easily beating Wall Street estimates and widening the gap with Danish rival Novo Nordisk.
Lilly beats estimates on resilient demand for injectable GLP-1 drugs
Source & full coverage: this summary is aggregated from Free Malaysia Today Business, the original publisher. Read the complete report for full context, data and quotes.
Read the original report at Free Malaysia Today Business →
